Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR)

L. Součková, R. Opatřilová, P. Suk, I. Čundrle, M. Pavlík, V. Zvoníček, O. Hlinomaz, V. Šrámek,

. 2013 ; 69 (3) : 309-17.

Language English Country Germany

Document type Journal Article

E-resources Online Full text

NLK ProQuest Central from 1997-01-01 to 1 year ago
CINAHL Plus with Full Text (EBSCOhost) from 2008-01-01 to 1 year ago
Medline Complete (EBSCOhost) from 2000-01-01 to 1 year ago
Nursing & Allied Health Database (ProQuest) from 1997-01-01 to 1 year ago
Health & Medicine (ProQuest) from 1997-01-01 to 1 year ago

PURPOSE: Bioavailability of clopidogrel in the form of crushed tablets administered via nasogastric tube (NGT) has not been established in patients after cardiopulmonary resuscitation. Therefore, we performed a study comparing pharmacokinetic and pharmacodynamic response to high loading dose of clopidogrel in critically ill patients after cardiopulmonary resuscitation (CPR) with patients scheduled for elective coronary angiography with stent implantation. METHODS: In the NGT group (nine patients, after cardiopulmonary resuscitation, mechanically ventilated, therapeutic hypothermia), clopidogrel was administered in the form of crushed tablets via NGT. Ten patients undergoing elective coronary artery stenting took clopidogrel per os (po) in the form of intact tablets. Pharmacokinetics of clopidogrel was measured with high-performance liquid chromatography (HPLC) before and at 0.5, 1, 6, 12, 24 h after administration of a loading dose of 600 mg. In five patients in each group, antiplatelet effect was measured with thrombelastography (TEG; Platelet Mapping) before and 24 h after administration. RESULTS: The carboxylic acid metabolite of clopidogrel was detected in all patients in the po group. In eight patients, the maximum concentration was measured in the range of 0.5-1 h after the initial dose. In four patients in the of NGT group, the carboxylic acid metabolite of clopidogrel was undetectable and in the remaining patients was significantly delayed (peak values at 12 h). All patients in the po group reached clinically relevant (>50 %) inhibition of thrombocyte adenosine diphosphate (ADP) receptor after 24 h compared with only two in the NGT group (p = 0.012). There was a close correlation between peak of inactive clopidogrel metabolite plasmatic concentration and inhibition of the ADP receptor (r = 0.79; p < 0.001). CONCLUSION: The bioavailability of clopidogrel in critically ill patients after cardiopulmonary resuscitation is significantly impaired compared with stable patients. Therefore, other drugs, preferentially administered intravenously, should be considered.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13031890
003      
CZ-PrNML
005      
20131004113019.0
007      
ta
008      
131002s2013 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00228-012-1360-0 $2 doi
035    __
$a (PubMed)22890586
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Součková, L $u Department of Anaesthesiology and Intensive Care, University Hospital St. Anne's Brno, Brno, Czech Republic.
245    10
$a Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR) / $c L. Součková, R. Opatřilová, P. Suk, I. Čundrle, M. Pavlík, V. Zvoníček, O. Hlinomaz, V. Šrámek,
520    9_
$a PURPOSE: Bioavailability of clopidogrel in the form of crushed tablets administered via nasogastric tube (NGT) has not been established in patients after cardiopulmonary resuscitation. Therefore, we performed a study comparing pharmacokinetic and pharmacodynamic response to high loading dose of clopidogrel in critically ill patients after cardiopulmonary resuscitation (CPR) with patients scheduled for elective coronary angiography with stent implantation. METHODS: In the NGT group (nine patients, after cardiopulmonary resuscitation, mechanically ventilated, therapeutic hypothermia), clopidogrel was administered in the form of crushed tablets via NGT. Ten patients undergoing elective coronary artery stenting took clopidogrel per os (po) in the form of intact tablets. Pharmacokinetics of clopidogrel was measured with high-performance liquid chromatography (HPLC) before and at 0.5, 1, 6, 12, 24 h after administration of a loading dose of 600 mg. In five patients in each group, antiplatelet effect was measured with thrombelastography (TEG; Platelet Mapping) before and 24 h after administration. RESULTS: The carboxylic acid metabolite of clopidogrel was detected in all patients in the po group. In eight patients, the maximum concentration was measured in the range of 0.5-1 h after the initial dose. In four patients in the of NGT group, the carboxylic acid metabolite of clopidogrel was undetectable and in the remaining patients was significantly delayed (peak values at 12 h). All patients in the po group reached clinically relevant (>50 %) inhibition of thrombocyte adenosine diphosphate (ADP) receptor after 24 h compared with only two in the NGT group (p = 0.012). There was a close correlation between peak of inactive clopidogrel metabolite plasmatic concentration and inhibition of the ADP receptor (r = 0.79; p < 0.001). CONCLUSION: The bioavailability of clopidogrel in critically ill patients after cardiopulmonary resuscitation is significantly impaired compared with stable patients. Therefore, other drugs, preferentially administered intravenously, should be considered.
650    _2
$a aplikace orální $7 D000284
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a biologická dostupnost $7 D001682
650    _2
$a trombocyty $x účinky léků $x metabolismus $7 D001792
650    12
$a kardiopulmonální resuscitace $7 D016887
650    _2
$a vysokoúčinná kapalinová chromatografie $7 D002851
650    _2
$a kritický stav $7 D016638
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a terapeutická hypotermie $7 D007036
650    _2
$a gastrointestinální intubace $7 D007441
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a koronární angioplastika $x přístrojové vybavení $7 D062645
650    _2
$a inhibitory agregace trombocytů $x aplikace a dávkování $x krev $x farmakokinetika $7 D010975
650    _2
$a antagonisté purinergního receptoru P2 $x aplikace a dávkování $x krev $x farmakokinetika $7 D058919
650    _2
$a purinergní receptory P2 $x účinky léků $x metabolismus $7 D018048
650    _2
$a umělé dýchání $7 D012121
650    _2
$a stenty $7 D015607
650    _2
$a tablety $7 D013607
650    _2
$a tromboelastografie $7 D013916
650    _2
$a tiklopidin $x aplikace a dávkování $x analogy a deriváty $x krev $x farmakokinetika $7 D013988
655    _2
$a časopisecké články $7 D016428
700    1_
$a Opatřilová, R $u -
700    1_
$a Suk, P $u -
700    1_
$a Čundrle, I $u -
700    1_
$a Pavlík, M $u -
700    1_
$a Zvoníček, V $u -
700    1_
$a Hlinomaz, O $u -
700    1_
$a Šrámek, V $u -
773    0_
$w MED00001613 $t European journal of clinical pharmacology $x 1432-1041 $g Roč. 69, č. 3 (2013), s. 309-17
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22890586 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20131002 $b ABA008
991    __
$a 20131004113538 $b ABA008
999    __
$a ok $b bmc $g 995977 $s 830335
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 69 $c 3 $d 309-17 $i 1432-1041 $m European journal of clinical pharmacology $n Eur J Clin Pharmacol $x MED00001613
LZP    __
$a Pubmed-20131002

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...